# Camrelizumab

Source: https://onco.cc/drugs/camrelizumab/  
OnCo record `camrelizumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Camrelizumab is Jiangsu Hengrui's humanised PD-1 antibody, approved in China for oesophageal, liver and lung cancer but not in the US, where its liver cancer combination with rivoceranib drew complete response letters in 2024 and 2025 over manufacturing and inspection issues. Its signature side effect is reactive cutaneous capillary endothelial proliferation, a skin reaction seen in most patients.

## Summary

Humanised IgG4 anti-PD-1 (Jiangsu Hengrui). ESCORT (second-line ESCC) and ESCORT-1st (first-line with chemotherapy, OS 15.3 vs 12.0 months) in China; ESCORT-NEO neoadjuvant; CARES-310 with rivoceranib in HCC (OS 22.1 vs 15.2 months). A US BLA for the HCC combination received complete response letters (2024, 2025) over manufacturing and travel-inspection issues. Distinctive toxicity: reactive cutaneous capillary endothelial proliferation (RCCEP) in most patients.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-07
- Brand: AiRuiKa
- Code: SHR-1210
- Modality: Monoclonal antibody (anti-PD-1)
- Mechanism: PD-1 blockade.
- Approvals: China 2019: Classical Hodgkin lymphoma; subsequently HCC, NSCLC, ESCC (second line 2020, first line with chemotherapy 2021), nasopharyngeal
- Dosing: Intravenous; 200 mg every 2-3 weeks

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Camrelizumab
- ESCORT-1st final analysis: https://pubmed.ncbi.nlm.nih.gov/38870932/

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)](https://onco.cc/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Recurrent and metastatic nasopharyngeal carcinoma](https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)
- terms: [Immune-related adverse events (irAEs)](https://onco.cc/terms/irae/)
- trials: [A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.](https://onco.cc/trials/nct07395063/), [A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients](https://onco.cc/trials/nct06335355/), [A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer](https://onco.cc/trials/nct06361888/), [A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS](https://onco.cc/trials/nct07527026/), [A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs](https://onco.cc/trials/nct06423170/), [A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BC](https://onco.cc/trials/nct05999149/), [A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma](https://onco.cc/trials/nct05320692/), [A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast](https://onco.cc/trials/nct04481763/), [A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recur](https://onco.cc/trials/nct04639180/), [A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC](https://onco.cc/trials/nct06632405/), [Adjuvant Chemotherapy Combined With Camrelizumab for IIA -IIIA NSCLC Patients](https://onco.cc/trials/nct05825443/), [Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metas](https://onco.cc/trials/nct05841472/), [CameL](https://onco.cc/trials/camel/), [Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma](https://onco.cc/trials/nct06901622/), [Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer](https://onco.cc/trials/nct04906993/), [Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer](https://onco.cc/trials/nct07107217/), [Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer](https://onco.cc/trials/nct05451290/), [CAPTAIN-1st](https://onco.cc/trials/captain-1st/), [Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer](https://onco.cc/trials/nct07159217/), [Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite](https://onco.cc/trials/nct06176885/), [ESCORT-1st](https://onco.cc/trials/escort-1st/), [Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.](https://onco.cc/trials/nct05760378/), [Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer](https://onco.cc/trials/nct06423937/), [FUSCC Refractory TNBC Platform Study (FUTURE2.0)](https://onco.cc/trials/nct05749588/), [HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer](https://onco.cc/trials/nct06849492/), [Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer](https://onco.cc/trials/nct06435260/), [JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC](https://onco.cc/trials/nct06731153/), [Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer](https://onco.cc/trials/nct06759090/), [Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer](https://onco.cc/trials/nct06196671/), [Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer](https://onco.cc/trials/nct06889688/), [Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer](https://onco.cc/trials/nct07521605/), [Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)](https://onco.cc/trials/nct05447702/), [Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC](https://onco.cc/trials/nct04342910/), [Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab](https://onco.cc/trials/nct06304545/)
- people: [Jing Huang](https://onco.cc/people/huang-jing-cams/), [Li Zhang](https://onco.cc/people/zhang-li-sysucc/), [Piaoyang Sun](https://onco.cc/people/sun-piaoyang/), [Rui-Hua Xu](https://onco.cc/people/xu-rui-hua/), [Wenfeng Fang](https://onco.cc/people/fang-wenfeng/)
- bottlenecks: [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/)
- collections: [CSCO guidelines (China)](https://onco.cc/collections/csco-guidelines/)
- key papers: [CAPTAIN-1st: camrelizumab versus placebo with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma](https://onco.cc/key-papers/paper-captain-1st-camrelizumab-chemotherapy-npc-lancet-oncol-2021/)
- drugs: [Rivoceranib (apatinib)](https://onco.cc/drugs/rivoceranib/)
- roadmaps: [Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation](https://onco.cc/roadmaps/global-access-roadmap/)
- pathways: [Hepatocellular carcinoma (KEGG map)](https://onco.cc/pathways/hepatocellular-carcinoma-signalling/)

---
JSON: https://onco.cc/api/v1/entities/camrelizumab.json